EGFR and non-small cell lung carcinoma: Most treatment-related AEs were grade 1-2 and manageable.<h4>Conclusions</h4>Dacomitinib demonstrated favorable efficacy and tolerability as a first-line therapy in advanced NSCLC patients with common EGFR mutations (exon 19 deletion or L858R).